desonide
Regulatory sources consulted
Approved indications
- Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Contraindications
Absolute
- Hypersensitivity to desonide or any component.
Clinical warnings
- Major warning · Systemic absorption may cause reversible HPA-axis suppression, Cushing syndrome, hyperglycemia, and glucosuria; risk increases with large areas, prolonged use, or occlusion. Children are more susceptible, and linear growth retardation, delayed weight gain, and intracranial hypertension have been reported. — DailyMed/openFDA, SPL set ID 0665dd04-1d0b-45bf-90e4-c6e0bd90956d
- Stop if irritation occurs. Treat any skin infection; if it does not respond promptly, stop the corticosteroid until infection is controlled. — DailyMed/openFDA, SPL set ID 0665dd04-1d0b-45bf-90e4-c6e0bd90956d
Adverse events
Common (≥1%)
Pruritus, pain, folliculitis, rash, erythema, irritation, or burning
Rare but serious
Hypothalamic–pituitary–adrenal axis suppression
Pregnancy and lactation
During pregnancy, use only if potential benefit justifies fetal risk and avoid extensive amounts or prolonged periods. Use cautiously during breastfeeding.
Recent literature (PubMed)
Post-inflammatory hyperpigmentation is a common dermatologic complaint that affects different parts of the body. Axillary hyperpigmentation (AH) is a common dermatologic complaint, with no standard treatment. We aim to address the efficacy and safety of the studied treatment modalities for AH. A systematic search was done using "axillary" and "hyperpigmentation"-related keywords/MeSH terms through PubMed/Medline, Scopus, Web of Science, and Embase. Ten studies on AH were categorized into topical treatments, light/laser-based therapies, and comparative approaches. Topical agents like niacinamide, desonide, sweet orange extract, Perilla frutescens leaf extract, Cyperus rotundus oil, glycolic acid, and novel serums demonstrated varying degrees of pigmentation reduction, with desonide and C. rotundus oil showing significant effectiveness and minimal side effects. Q-switched Nd:YAG laser was effective across three studies. Both Q-switched Nd:YAG laser and intense pulsed light (IPL) modalities showed significant improvement with minimal adverse events; though pain was more reported with the laser. A comparative study found IPL superior to alpha-hydroxy acid in skin lightening and texture improvement. One study on Curcuma aeruginosa was excluded due to its primary focus on hair growth reduction rather than pigmentation. The most frequently used laser in treating AH was QS Nd-YAG without having any severe adverse effect. Various topical treatments including Niacinamide, desonide, HQ, AHA, and a few herbal extracts were shown to be effective for AH.
Skin-blanching assay has been established as a surrogate method for assessing bioequivalence of topical corticosteroids. This study aimed to apply the skin-blanching assay to evaluate the bioequivalence of a test desonide cream (T) compared with the reference Desonide® (R) using Chinese skins. Additionally, the pharmacokinetics and safety profiles were also assessed. By detecting the degree of skin blanching under different dose durations in a pilot dose-duration-response study, the area under the observed effect-time curve (AUEC) and half of the maximum effect (ED50) was calculated. Based on this, the skin color of different time points after a dose duration of ED50, D1 (0.5 × ED50), and D2 (2 × ED50) were detected as a pharmacodynamic indicator to compare between test and reference creams. Single-center, single-dose, randomized, open-label, two-cycle crossover pharmacokinetic studies were designed to make sure the exposure of tested formulationswas not higher than that of the reference formulations. Subjects experiencing adverse events (AEs) were monitored and utilized for safety analysis. These studies involved 12 subjects for the dose-duration-response study, 100 subjects for the bioequivalence study, and 12 subjects for the pharmacokinetic study. The results showed that the population ED50 was 0.88 ± 0.45 h; the mean ratio of area under effective curve from 0 to 24 h (AUEC0-24h) of test and reference preparations was 0.95, with a 90% confidence interval as 88.09-101.72%, indicating the bioequivalence of the test formulation and Desonide®. The maximum plasma concentration (Cmax) and area under the concentration time curve from time 0 to the last time point (AUC0-t) of T and R were 20.8 ± 11.5 pg/mL versus 19.7 ± 10.1 pg/mL, respectively, and 451.04 ± 363.65 pgh/mL versus 541.47 ± 581.41 pgh/mL, respectively. The systemic exposure of a single dose of the test cream was not higher than that of the reference preparation. All of the volunteers experienced grade 1 AE
Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is characterized by intense pruritus and varying degrees of cutaneous inflammation. Current therapeutic modalities (such as topical corticosteroids and biologics) can control symptoms in the short term, but limitations including extremely low bioavailability and significant side effects substantially restrict their clinical efficacy in AD management. Therefore, more precise and safer local management strategies for AD represent the most promising direction for future development. As a biomaterial with a three-dimensional network structure combining biomimetic properties and sustained drug delivery capability, hydrogel emerges as an optimal carrier choice. Multiple clinical trials have demonstrated that Desonide hydrogel provides substantial benefits to patients, making the design of multifunctional hydrogel dressings a research hotspot in recent years. This review first summarizes the feasible options for drug loading in hydrogels, then focuses on the advantages and disadvantages of different hydrogel types and drug delivery methods, and finally addresses the challenges and solutions for translating innovative hydrogels into clinical practice. Aimed at integrating perspectives from materials science, dermatology, and translational medicine, this review establishes a theoretical framework for the rational design of innovative hydrogels in local AD therapy.
This study evaluates the efficacy and safety of soothing moisturizing repairing cream combined with desonide in the treatment of atopic dermatitis (AD) in children in the real world. A total of 37 children with AD were randomly divided into experimental (17) and control (20) groups. For the experimental group, treated with moisturizing cream combined with desonide cream, the maintenance period was with moisturizer alone. For the control group, treated solely with desonide, the maintenance period was with nothing. Clinical assessments were made before and 1, 2, and 4 weeks after treatment. Efficacy indicators are compared between the 2 groups, and the relieving effect of moisturizer on the maintenance period of AD in children is observed. Adverse reactions are also recorded. After 4 weeks of treatment, the cure rate and effectiveness rate in the experimental group were 52.9% and 100%, respectively, compared to 0% and 60% in the control group; the estimated median maintenance time was 48 days for the control group and 73 days for the experimental group. The incidence of adverse reactions shows no statistical significance. The combination of moisturizing cream and desonide in the treatment of AD in children is highly effective and safe. It is worth promoting for clinical application due to its significant therapeutic effects and high safety profile.
The current nursing procedure after fractional carbon dioxide (fCO2) is complex and needs to be optimized. The present study was conducted to evaluate the assisting effect of filament coating system after fCO2 laser treatment. Chinese individuals aged from 18 to 65 years diagnosed as photoaging or atrophic acne scar were recruited and each participant was treated with one single pass of fCO2 laser. A split face was randomly assigned as treatment side or control side. For control side, conventional procedure was topically applied respectively, including desonide cream two times for 3 days, fusidic acid cream two times for 7 days, and recombinant human epidermal growth factor (RhEGF) gel four times for 7 days; for treating side, a filament coating system was applied immediately after one application of fusidic acid cream, desonide cream and RhEGF, and removed 3 h later, for 3 days. Erythema, edema, crust, and pain on both sides were scored from 0 to 10 before and 1, 2, 4, and 7 days after fCO2 laser treatment. Stratum corneum hydration (SCH) and sebum of forehead and cheek on both sides were also measured by using Corneometer-Sebumeter. Twenty photoaging and 11 atrophic acne scar participants finished the observation. All of them complained of erythema, edema, crust, and pain after fCO2 laser treatment, and the scores decreased as time passed by. There were no statistical significances of erythema, edema, crust, pain, SCH, and sebum between treating side and control side at each observation time. Filament coating system was effective, safe, convenient, and economic in assisting recovery of ablative fCO2 laser, which might be a new option for additional nursing procedure.